A Phase 2 interventional study of PF-06651600 and PF-06700841 in Alopecia Areata, sponsored by Pfizer. Completed at 55 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-26.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.
Among the 17 studies in Alopecia Areata by Pfizer, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2, and was the 1st registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Pfizer · Sites in United States, China, Czechia and 6 more countries
Ages 6–14
Pfizer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in United States, Canada, China and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 175 across the 10 interventional studies, 375 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Alopecia Areata by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alopecia Areata by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind) Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension Period and a 4 week Follow up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated .
Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.
Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal medications with unknown properties or known beneficial effects for AA.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-06651600
Drug: PF-06651600
PF-06700841
Drug: PF-06700841
placebo
Drug: Placebo
200 mg QD during induction and 50 mg QD during Maintenance
60 mg QD during induction and 30 mg QD during maintenance
Placebo
Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).
Time frame: Baseline, Week24
Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with "withdrawal Segment" and "retreatment segment" described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.
Time frame: Week 28 up to Week 52
Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.
Time frame: COE day 1 up to end of study
Number of Participants With Laboratory Abnormalities During SBE Period
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
Time frame: Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)
Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
Time frame: COE day 1 up to end of study
Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were "none" at baseline.
Time frame: Baseline, Week 24
Percentage of Participants Achieving SALT 30 at Week 24
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.
Time frame: Baseline, Week 24
Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.
Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.
Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
Number of Participants With the IGA Score Change (Treatment Period)
The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).
Time frame: baseline, Week 2,4,6,8,12,16,20,24
Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.
Time frame: baseline up to Week 24
Number of Participants With Laboratory Abnormalities During Treatment Period
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
Time frame: Baseline up to Week 24
Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)
Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.
Time frame: Week 24 up to Week 52
Change From Baseline in SALT Across Time (SBE Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.
Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Percentage of Participants Achieving SALT 30 Across Time (SBE Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Percentage of Participants Achieving SALT 50 Across Time (SBE Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Percentage of Participants Achieving SALT 75 Across Time (SBE Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Percentage of Participants Achieving SALT 90 Across Time (SBE Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Percentage of Participants Achieving SALT 100 Across Time (SBE Period)
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
The study had a 24 week Treatment Period, a 4 week Drug Holiday, an up to 48 weeks(24 weeks + additional 24 Weeks for those received active retreatment) Single Blind Extension Period, a 4 week Drug Holiday, a 24 weeks Cross Over Open Label Extension Period.
| Milestone | Placebo for PF-06651600 | Placebo for PF-06700841 | PF-06651600 | PF-06700841 |
|---|---|---|---|---|
| Started | 24 | 23 | 48 | 47 |
| Completed | 20 | 14 | 45 | 35 |
| Not completed | 4 | 9 | 3 | 12 |
| Withdrew: Adverse event | 1 | 1 | 2 | 4 |
| Withdrew: Others | 3 | 8 | 1 | 8 |
| Milestone | Placebo for PF-06651600 | Placebo for PF-06700841 | PF-06651600 | PF-06700841 |
|---|---|---|---|---|
| Started | 17 | 12 | 38 | 29 |
| Completed | 15 | 11 | 27 | 23 |
| Not completed | 2 | 1 | 11 | 6 |
| Withdrew: Ae & withdraw by participants | 2 | 1 | 11 | 6 |
| Milestone | Placebo for PF-06651600 | Placebo for PF-06700841 | PF-06651600 | PF-06700841 |
|---|---|---|---|---|
| Started | 7 | 2 | 11 | 3 |
| Completed | 5 | 1 | 8 | 3 |
| Not completed | 2 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 0 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).
| units on a scale | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 | 32.54 (25.35 to 39.74) | 50.59 (43.15 to 58.02) | 1.41 (-6.03 to 8.85) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were "none" at baseline.
| units on a scale | PF-06651600-AT/AU | PF-06700841-AT/AU | Placebo-AT/AU |
|---|---|---|---|
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants | 27.59 (15.24 to 39.94) | 48.42 (36.38 to 60.47) | 1.81 (-11.00 to 14.63) |
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with "withdrawal Segment" and "retreatment segment" described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.
| Participants | Active Non-responders on PF-06651600 | Placebo Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06700841 | Non-Retreated PF-06651600 Responders in the Withdrawal Segment | Retreated PF-06651600 Responders in the Withdrawal Segment | Non-Retreated PF-06700841 Responders in the Withdrawal Segment | Retreated PF-06700841 Responders in the Withdrawal Segment | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|---|---|---|---|
| TEAE (All Causalities) | 8 | 12 | 4 | 10 | 4 | 3 | 6 | 9 | 11 | 9 |
| TEAE (Treatment Related) | 5 | 1 | 0 | 1 | 0 | 1 | 0 | 3 | 2 | 2 |
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.
| Participants | COE-PF-06651600 | COE-PF-06700841 |
|---|---|---|
| TEAE (All Causalities) | 4 | 9 |
| TEAE (Treatment Related) | 2 | 3 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
| Participants | Active Non-responders on PF-06651600 | Placebo Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06700841 | Non-Retreated PF-06651600 Responders in the Withdrawal Segment | Retreated PF-06651600 Responders in the Withdrawal Segment | Non-Retreated PF-06700841 Responders in the Withdrawal Segment | Retreated PF-06700841 Responders in the Withdrawal Segment | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|---|---|---|---|
| With abnormalities without regard to baseline | 13 | 11 | 4 | 11 | 6 | 9 | 7 | 10 | 11 | 14 |
| Meeting Retest Criteria | 3 | 5 | 2 | 7 | 2 | 0 | 3 | 2 | 4 | 4 |
| Meeting Discontinuation Criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
| Participants | COE-PF-06651600 | COE-PF-06700841 |
|---|---|---|
| With abnormalities without regard to baseline | 5 | 11 |
| Meeting Retest Criteria | 1 | 6 |
| Meeting Discontinuation Criteria | 0 | 0 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving SALT 30 at Week 24 | 50.0 (37.6 to 62.4) | 63.8 (51.3 to 74.9) | 2.1 (0.2 to 8.8) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.
| units on a scale | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Week 2 | -0.74 (-2.06 to 0.59) | -0.93 (-2.27 to 0.40) | 1.18 (0.23 to 2.13) |
| Week 4 | 2.93 (-1.32 to 7.17) | 7.70 (3.43 to 11.97) | 0.85 (-2.20 to 3.90) |
| Week 6 | 12.44 (5.42 to 19.45) | 19.37 (12.29 to 26.45) | 1.32 (-3.72 to 6.35) |
| Week 8 | 18.49 (9.57 to 27.41) | 29.30 (20.28 to 38.32) | 1.77 (-4.63 to 8.17) |
| Week 12 | 24.49 (14.90 to 34.09) | 36.57 (26.86 to 46.29) | 1.62 (-5.26 to 8.50) |
| Week 16 | 27.59 (17.67 to 37.50) | 41.16 (31.11 to 51.22) | 1.61 (-5.49 to 8.72) |
| Week 20 | 29.32 (19.06 to 39.57) | 45.55 (35.14 to 55.97) | 1.62 (-5.73 to 8.98) |
| Week 24 | 31.14 (20.79 to 41.49) | 49.18 (38.66 to 59.70) | 1.41 (-6.03 to 8.85) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.
| percent change | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Week 2 | -0.76 (-2.26 to 0.75) | -1.13 (-2.64 to 0.39) | 1.26 (0.18 to 2.33) |
| Week 4 | 3.99 (-0.86 to 8.83) | 9.70 (4.83 to 14.57) | 0.53 (-2.96 to 4.01) |
| Week 6 | 15.88 (7.84 to 23.91) | 22.88 (14.77 to 30.99) | 1.02 (-4.75 to 6.80) |
| Week 8 | 23.22 (13.15 to 33.29) | 34.78 (24.59 to 44.96) | 1.31 (-5.91 to 8.54) |
| Week 12 | 30.99 (19.93 to 42.05) | 44.17 (32.97 to 55.37) | 0.99 (-6.94 to 8.92) |
| Week 16 | 35.14 (23.65 to 46.62) | 49.99 (38.35 to 61.64) | 0.86 (-7.38 to 9.09) |
| Week 20 | 37.31 (25.37 to 49.25) | 55.46 (43.34 to 67.58) | 0.91 (-7.65 to 9.47) |
| Week 24 | 39.67 (27.66 to 51.68) | 59.71 (47.51 to 71.92) | 0.43 (-8.20 to 9.06) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Week 2 | -2.1 (-9.7 to 3.7) | -2.1 (-9.7 to 3.5) | 2.1 (0.2 to 8.8) |
| Week 4 | 6.2 (-2.3 to 15.8) | 12.8 (3.0 to 24.0) | 2.1 (0.2 to 8.8) |
| Week 6 | 18.7 (7.0 to 31.0) | 27.7 (15.4 to 40.4) | 2.1 (0.2 to 8.8) |
| Week 8 | 25.0 (13.2 to 37.4) | 38.3 (25.8 to 51.4) | 2.1 (0.2 to 8.8) |
| Week 12 | 39.5 (26.4 to 52.6) | 48.9 (35.8 to 61.8) | 2.1 (0.2 to 8.8) |
| Week 16 | 45.8 (32.2 to 58.7) | 55.3 (42.0 to 67.8) | 2.1 (0.2 to 8.8) |
| Week 20 | 47.9 (34.2 to 60.7) | 59.6 (46.3 to 71.7) | 2.1 (0.2 to 8.8) |
| Week 24 | 47.9 (34.2 to 60.7) | 61.7 (48.2 to 73.6) | 2.1 (0.2 to 8.8) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Week 2 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 4 | 0.0 (-6.2 to 6.1) | 10.6 (3.6 to 21.1) | 0 (0.0 to 5.7) |
| Week 6 | 10.4 (1.1 to 21.1) | 17.0 (6.5 to 28.8) | 2.1 (0.2 to 8.8) |
| Week 8 | 18.7 (7.0 to 31.0) | 29.8 (17.2 to 42.7) | 2.1 (0.2 to 8.8) |
| Week 12 | 27.0 (15.0 to 39.6) | 36.2 (23.8 to 49.2) | 2.1 (0.2 to 8.8) |
| Week 16 | 33.3 (20.3 to 46.2) | 40.4 (27.8 to 53.5) | 2.1 (0.2 to 8.8) |
| Week 20 | 33.3 (20.3 to 46.2) | 46.8 (33.8 to 59.8) | 2.1 (0.2 to 8.8) |
| Week 24 | 37.5 (24.5 to 50.6) | 51.1 (37.9 to 63.8) | 2.1 (0.2 to 8.8) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Week 2 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 4 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 6 | 8.3 (1.8 to 18.1) | 10.6 (3.6 to 21.1) | 0 (0.0 to 5.7) |
| Week 8 | 12.5 (2.8 to 23.6) | 23.4 (11.8 to 36.2) | 2.1 (0.2 to 8.8) |
| Week 12 | 16.6 (6.3 to 28.6) | 27.7 (15.4 to 40.4) | 2.1 (0.2 to 8.8) |
| Week 16 | 20.8 (8.6 to 33.0) | 31.9 (19.0 to 44.9) | 2.1 (0.2 to 8.8) |
| Week 20 | 25.0 (13.2 to 37.4) | 38.3 (25.8 to 51.4) | 2.1 (0.2 to 8.8) |
| Week 24 | 27.0 (15.0 to 39.6) | 40.4 (27.8 to 53.5) | 2.1 (0.2 to 8.8) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Week 2 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 4 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 6 | 0.0 (-6.2 to 6.1) | 6.4 (0.2 to 15.7) | 0 (0.0 to 5.7) |
| Week 8 | 4.2 (-2.0 to 12.5) | 12.8 (5.2 to 23.6) | 0 (0.0 to 5.7) |
| Week 12 | 10.4 (3.4 to 20.7) | 25.5 (15.4 to 38.1) | 0 (0.0 to 5.7) |
| Week 16 | 16.7 (8.6 to 27.7) | 27.7 (17.2 to 40.3) | 0 (0.0 to 5.7) |
| Week 20 | 18.7 (7.0 to 31.0) | 29.8 (17.2 to 42.7) | 2.1 (0.2 to 8.8) |
| Week 24 | 25.0 (15.1 to 37.3) | 34.0 (22.7 to 47.0) | 0 (0.0 to 5.7) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Week 2 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 4 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 6 | 0.0 (-6.2 to 6.1) | 0.0 (-6.2 to 6.2) | 0 (0.0 to 5.7) |
| Week 8 | 0.0 (-6.2 to 6.1) | 2.1 (-3.5 to 9.7) | 0 (0.0 to 5.7) |
| Week 12 | 2.1 (-3.8 to 9.5) | 6.4 (0.2 to 15.7) | 0 (0.0 to 5.7) |
| Week 16 | 2.1 (-3.8 to 9.5) | 8.5 (1.9 to 18.4) | 0 (0.0 to 5.7) |
| Week 20 | 4.2 (-2.0 to 12.5) | 12.8 (5.2 to 23.6) | 0 (0.0 to 5.7) |
| Week 24 | 12.5 (5.1 to 23.2) | 12.8 (5.2 to 23.6) | 0 (0.0 to 5.7) |
The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).
| Participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| Baseline — 0 (NO CHANGE OR FURTHER LOSS) | 48 | 47 | 47 |
| Baseline — 1 (1-24% REGROWTH) | 0 | 0 | 0 |
| Baseline — 2 (25-49% REGROWTH) | 0 | 0 | 0 |
| Baseline — 3 (50-74% REGROWTH) | 0 | 0 | 0 |
| Baseline — 4 (75-99% REGROWTH) | 0 | 0 | 0 |
| Baseline — 5 (100% REGROWTH) | 0 | 0 | 0 |
| Week 2 — 0 (NO CHANGE OR FURTHER LOSS) | 40 | 43 | 40 |
| Week 2 — 1 (1-24% REGROWTH) | 8 | 4 | 5 |
| Week 2 — 2 (25-49% REGROWTH) | 0 | 0 | 1 |
| Week 2 — 3 (50-74% REGROWTH) | 0 | 0 | 0 |
| Week 2 — 4 (75-99% REGROWTH) | 0 | 0 | 0 |
| Week 2 — 5 (100% REGROWTH) | 0 | 0 | 0 |
| Week 4 — 0 (NO CHANGE OR FURTHER LOSS) | 29 | 21 | 36 |
| Week 4 — 1 (1-24% REGROWTH) | 15 | 19 | 6 |
| Week 4 — 2 (25-49% REGROWTH) | 4 | 2 | 1 |
| Week 4 — 3 (50-74% REGROWTH) | 0 | 5 | 0 |
| Week 4 — 4 (75-99% REGROWTH) | 0 | 0 | 0 |
| Week 4 — 5 (100% REGROWTH) | 0 | 0 | 0 |
| Week 6 — 0 (NO CHANGE OR FURTHER LOSS) | 16 | 10 | 35 |
| Week 6 — 1 (1-24% REGROWTH) | 18 | 17 | 6 |
| Week 6 — 2 (25-49% REGROWTH) | 7 | 9 | 1 |
| Week 6 — 3 (50-74% REGROWTH) | 2 | 4 | 1 |
| Week 6 — 4 (75-99% REGROWTH) | 4 | 5 | 0 |
| Week 6 — 5 (100% REGROWTH) | 0 | 0 | 0 |
| Week 8 — 0 (NO CHANGE OR FURTHER LOSS) | 13 | 7 | 33 |
| Week 8 — 1 (1-24% REGROWTH) | 17 | 17 | 9 |
| Week 8 — 2 (25-49% REGROWTH) | 7 | 5 | 1 |
| Week 8 — 3 (50-74% REGROWTH) | 3 | 3 | 0 |
| Week 8 — 4 (75-99% REGROWTH) | 7 | 11 | 1 |
| Week 8 — 5 (100% REGROWTH) | 0 | 1 | 0 |
| Week 12 — 0 (NO CHANGE OR FURTHER LOSS) | 13 | 6 | 33 |
| Week 12 — 1 (1-24% REGROWTH) | 11 | 11 | 10 |
| Week 12 — 2 (25-49% REGROWTH) | 9 | 9 | 1 |
| Week 12 — 3 (50-74% REGROWTH) | 5 | 4 | 0 |
| Week 12 — 4 (75-99% REGROWTH) | 8 | 10 | 1 |
| Week 12 — 5 (100% REGROWTH) | 1 | 4 | 0 |
| Week 16 — 0 (NO CHANGE OR FURTHER LOSS) | 14 | 5 | 31 |
| Week 16 — 1 (1-24% REGROWTH) | 7 | 7 | 9 |
| Week 16 — 2 (25-49% REGROWTH) | 7 | 9 | 1 |
| Week 16 — 3 (50-74% REGROWTH) | 6 | 4 | 0 |
| Week 16 — 4 (75-99% REGROWTH) | 10 | 11 | 1 |
| Week 16 — 5 (100% REGROWTH) | 1 | 5 | 0 |
| Week 20 — 0 (NO CHANGE OR FURTHER LOSS) | 14 | 4 | 29 |
| Week 20 — 1 (1-24% REGROWTH) | 6 | 6 | 9 |
| Week 20 — 2 (25-49% REGROWTH) | 8 | 7 | 1 |
| Week 20 — 3 (50-74% REGROWTH) | 4 | 4 | 0 |
| Week 20 — 4 (75-99% REGROWTH) | 10 | 11 | 1 |
| Week 20 — 5 (100% REGROWTH) | 3 | 8 | 0 |
| Week 24 — 0 (NO CHANGE OR FURTHER LOSS) | 13 | 4 | 27 |
| Week 24 — 1 (1-24% REGROWTH) | 5 | 6 | 6 |
| Week 24 — 2 (25-49% REGROWTH) | 7 | 5 | 1 |
| Week 24 — 3 (50-74% REGROWTH) | 5 | 5 | 0 |
| Week 24 — 4 (75-99% REGROWTH) | 8 | 13 | 1 |
| Week 24 — 5 (100% REGROWTH) | 6 | 7 | 0 |
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.
| Participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| TEAE (All Causalities) | 32 | 36 | 35 |
| TEAE (Treatment Related) | 13 | 20 | 14 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
| Participants | PF-06651600 | PF-06700841 | Placebo |
|---|---|---|---|
| With abnormalities without regard to baseline | 35 | 36 | 32 |
| Meeting Safety Criteria | 12 | 29 | 5 |
| Meeting Retest Criteria | 5 | 18 | 9 |
| Meeting Discontinuation Criteria | 0 | 3 | 0 |
Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.
| Weeks | PF-06651600 Responders | PF-06700841 Responders |
|---|---|---|
| Q1 time to retreatment (25th percentile of time) | 10.1 (4.3 to 12.6) | 11.0 (4.1 to 16.1) |
| Median time to retreatment | 16.1 (10.1 to 20.3) | 24.1 (14.6 to NA) |
| Q3 time to retreatment (75th percentile of time) | 21.1 (16.1 to NA) | NA (24.3 to NA) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.
| unit on a scale | Active Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06651600 | Placebo Non-responders on PF-06700841 | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|
| Week 30/ AT Week 2 | 1.76 (-4.47 to 7.99) | 0.09 (-9.83 to 10.01) | 2.99 (-4.56 to 10.54) | -0.31 (-9.53 to 8.92) | 25.04 (15.01 to 35.08) | 19.83 (10.00 to 29.66) |
| Week 32/ AT Week 4 | 1.85 (-4.37 to 8.07) | 2.22 (-7.78 to 12.21) | 3.37 (-4.06 to 10.79) | 3.71 (-4.93 to 12.35) | 27.63 (17.67 to 37.59) | 15.66 (5.82 to 25.51) |
| Week 34/ AT Week 6 | 1.80 (-4.42 to 8.02) | 3.16 (-6.90 to 13.23) | 10.16 (2.55 to 17.77) | 24.67 (16.00 to 33.34) | 33.78 (23.72 to 43.83) | 20.09 (10.17 to 30.02) |
| Week 36/ AT Week 8 | 2.16 (-4.09 to 8.40) | 3.01 (-7.12 to 13.14) | 8.93 (1.34 to 16.52) | 42.32 (33.37 to 51.28) | 38.80 (28.75 to 48.84) | 27.35 (17.42 to 37.27) |
| Week 40/ AT Week 12 | 3.35 (-2.91 to 9.61) | 3.19 (-7.00 to 13.38) | 18.30 (10.73 to 25.86) | 50.27 (41.65 to 58.90) | 43.70 (33.58 to 53.82) | 39.28 (29.36 to 49.19) |
| Week 44/ AT Week 16 | 3.41 (-2.84 to 9.67) | 3.12 (-7.19 to 13.43) | 25.71 (17.70 to 33.72) | 54.69 (45.73 to 63.64) | 48.93 (38.59 to 59.27) | 50.58 (40.48 to 60.69) |
| Week 48/ AT Week 20 | 4.70 (-1.57 to 10.97) | 2.97 (-7.39 to 13.34) | 25.28 (17.42 to 33.13) | 62.45 (53.13 to 71.77) | 53.74 (43.39 to 64.09) | 53.79 (43.57 to 64.02) |
| Week 52/ AT Week 24 | 7.06 (0.75 to 13.38) | 3.01 (-7.47 to 13.49) | 28.88 (20.20 to 37.56) | 58.53 (49.42 to 67.63) | 55.94 (45.42 to 66.46) | 58.37 (48.11 to 68.64) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
| percent of participants | Active Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06651600 | Placebo Non-responders on PF-06700841 | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|
| Week 30/ AT Week 2 | 4.1 (-5.3 to 23.0) | -2.1 (-10.9 to 40.0) | 3.8 (-5.5 to 21.6) | -2.1 (-9.7 to 18.9) | 47.9 (25.3 to 70.0) | 31.2 (12.8 to 54.0) |
| Week 32/ AT Week 4 | 4.1 (-5.3 to 23.0) | -2.1 (-10.9 to 40.0) | 9.6 (-2.4 to 30.2) | 14.5 (0.4 to 39.4) | 62.2 (38.2 to 81.5) | 11.2 (-1.0 to 33.5) |
| Week 34/ AT Week 6 | 4.1 (-5.3 to 23.0) | -2.1 (-10.9 to 40.0) | 21.4 (4.8 to 43.2) | 31.2 (10.9 to 57.0) | 69.3 (45.3 to 86.5) | 31.2 (12.8 to 54.0) |
| Week 36/ AT Week 8 | 4.1 (-5.3 to 23.0) | -2.1 (-10.9 to 40.0) | 21.4 (4.8 to 43.2) | 56.2 (30.8 to 78.2) | 69.3 (45.3 to 86.5) | 44.5 (23.2 to 66.5) |
| Week 40/ AT Week 12 | 10.4 (-1.5 to 31.8) | -2.1 (-10.9 to 40.0) | 27.3 (8.5 to 49.6) | 81.2 (55.6 to 94.4) | 62.2 (38.2 to 81.5) | 51.2 (28.9 to 72.2) |
| Week 44/ AT Week 16 | 10.4 (-1.5 to 31.8) | -2.1 (-10.9 to 40.0) | 33.2 (15.2 to 54.5) | 64.5 (38.4 to 84.5) | 62.2 (38.2 to 81.5) | 51.2 (28.9 to 72.2) |
| Week 48/ AT Week 20 | 10.4 (-1.5 to 31.8) | -2.1 (-10.9 to 40.0) | 39.0 (20.0 to 60.1) | 64.5 (38.4 to 84.5) | 69.3 (45.3 to 86.5) | 51.2 (28.9 to 72.2) |
| Week 52/ AT Week 24 | 10.4 (-1.5 to 31.8) | -2.1 (-10.9 to 40.0) | 27.3 (8.5 to 49.6) | 64.5 (38.4 to 84.5) | 55.0 (31.6 to 76.0) | 51.2 (28.9 to 72.2) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | Active Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06651600 | Placebo Non-responders on PF-06700841 | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|
| Week 30/ AT Week 2 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 14.3 (2.4 to 38.5) | 20.0 (5.7 to 44.0) |
| Week 32/ AT Week 4 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 21.4 (6.1 to 46.6) | 6.7 (-2.1 to 27.9) |
| Week 34/ AT Week 6 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 9.6 (-2.4 to 30.2) | 31.2 (10.9 to 57.0) | 26.4 (6.1 to 50.0) | 11.2 (-1.0 to 33.5) |
| Week 36/ AT Week 8 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 3.8 (-5.5 to 21.6) | 56.2 (30.8 to 78.2) | 33.6 (14.1 to 57.2) | 24.5 (5.6 to 47.1) |
| Week 40/ AT Week 12 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 15.5 (1.1 to 36.8) | 56.2 (30.8 to 78.2) | 47.9 (25.3 to 70.0) | 44.5 (23.2 to 66.5) |
| Week 44/ AT Week 16 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 21.4 (4.8 to 43.2) | 64.5 (38.4 to 84.5) | 47.9 (25.3 to 70.0) | 44.5 (23.2 to 66.5) |
| Week 48/ AT Week 20 | 4.1 (-5.3 to 23.0) | -2.1 (-10.9 to 40.0) | 27.3 (8.5 to 49.6) | 64.5 (38.4 to 84.5) | 47.9 (25.3 to 70.0) | 37.9 (17.9 to 60.3) |
| Week 52/ AT Week 24 | 4.1 (-5.3 to 23.0) | -2.1 (-10.9 to 40.0) | 27.3 (8.5 to 49.6) | 64.5 (38.4 to 84.5) | 47.9 (25.3 to 70.0) | 44.5 (23.2 to 66.5) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | Active Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06651600 | Placebo Non-responders on PF-06700841 | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|
| Week 30/ AT Week 2 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 32/ AT Week 4 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 7.1 (-1.9 to 29.7) | 0.0 (-6.6 to 18.1) |
| Week 34/ AT Week 6 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 8.3 (-1.5 to 33.9) | 14.3 (2.4 to 38.5) | 6.7 (-2.1 to 27.9) |
| Week 36/ AT Week 8 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | -2.1 (-9.7 to 13.3) | 22.9 (2.8 to 48.7) | 26.4 (6.1 to 50.0) | 17.9 (1.8 to 40.6) |
| Week 40/ AT Week 12 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 3.8 (-5.5 to 21.6) | 39.5 (17.0 to 64.5) | 26.4 (6.1 to 50.0) | 31.2 (12.8 to 54.0) |
| Week 44/ AT Week 16 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 15.5 (1.1 to 36.8) | 56.2 (30.8 to 78.2) | 26.4 (6.1 to 50.0) | 37.9 (17.9 to 60.3) |
| Week 48/ AT Week 20 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 15.5 (1.1 to 36.8) | 64.5 (38.4 to 84.5) | 28.6 (6.1 to 50.0) | 37.9 (17.9 to 60.3) |
| Week 52/ AT Week 24 | 4.1 (-5.3 to 23.0) | -2.1 (-10.9 to 40.0) | 27.3 (8.5 to 49.6) | 64.5 (38.4 to 84.5) | 33.6 (14.1 to 57.2) | 37.9 (17.9 to 60.3) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | Active Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06651600 | Placebo Non-responders on PF-06700841 | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|
| Week 30/ AT Week 2 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 32/ AT Week 4 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 34/ AT Week 6 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 36/ AT Week 8 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 8.3 (-1.5 to 33.9) | 7.1 (-1.9 to 29.7) | 6.7 (-2.1 to 27.9) |
| Week 40/ AT Week 12 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 25.0 (7.2 to 52.7) | 14.3 (2.4 to 38.5) | 13.3 (2.1 to 36.3) |
| Week 44/ AT Week 16 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 33.3 (12.3 to 60.9) | 21.4 (6.1 to 46.6) | 20.0 (5.7 to 44.0) |
| Week 48/ AT Week 20 | -2.1 (-9.7 to 13.8) | -2.1 (-10.9 to 40.0) | 3.8 (-5.5 to 21.6) | 47.9 (23.6 to 71.6) | 26.4 (6.1 to 50.0) | 24.5 (5.6 to 47.1) |
| Week 52/ AT Week 24 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 17.6 (5.0 to 39.6) | 50.0 (24.5 to 75.5) | 28.6 (10.4 to 54.0) | 40.0 (19.1 to 64.0) |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
| percentage of participants | Active Non-responders on PF-06651600 | Active Non-responders on PF-06700841 | Placebo Non-responders on PF-06651600 | Placebo Non-responders on PF-06700841 | Retreated PF-06651600 Responders in the Retreatment Segment | Retreated Responders on PF-06700841 in the Retreatment Segment |
|---|---|---|---|---|---|---|
| Week 30/ AT Week 2 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 32/ AT Week 4 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 34/ AT Week 6 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 36/ AT Week 8 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 0.0 (-6.3 to 22.1) | 0.0 (-6.8 to 19.3) | 0.0 (-6.6 to 18.1) |
| Week 40/ AT Week 12 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 8.3 (-1.5 to 33.9) | 7.1 (-1.9 to 29.7) | 0.0 (-6.6 to 18.1) |
| Week 44/ AT Week 16 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 8.3 (-1.5 to 33.9) | 7.1 (-1.9 to 29.7) | 13.3 (2.1 to 36.3) |
| Week 48/ AT Week 20 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 8.3 (-1.5 to 33.9) | 7.1 (-1.9 to 29.7) | 20.0 (5.7 to 44.0) |
| Week 52/ AT Week 24 | 0.0 (-6.3 to 17.1) | 0.0 (-7.4 to 45.1) | 0.0 (-6.2 to 16.2) | 8.3 (-1.5 to 33.9) | 14.3 (2.4 to 38.5) | 20.0 (5.7 to 44.0) |
Collected over From first dose of study treatment up to 113 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period-Placebo | 0/47 (0%) | 0/47 (0%) | 26/47 (55.3%) |
| Treatment Period-PF-06651600 | 0/48 (0%) | 0/48 (0%) | 23/48 (47.9%) |
| Treatment Period-PF-06700841 | 0/47 (0%) | 2/47 (4.3%) | 28/47 (59.6%) |
| Single Blind Extension-Active Non-responders on PF-06651600 | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Single Blind Extension-Placebo Non-responders on PF-06651600 | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| Single Blind Extension-Active Non-responders on PF-06700841 | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Single Blind Extension-Placebo Non-responders on PF-06700841 | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| SBE-Non-Retreated PF-06651600 Responders in Withdrawal Segment | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| SBE-Retreated PF-06651600 Responders in Withdrawal Segment | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| SBE-Non-Retreated PF-06700841 Responders (Withdrawal Segment) | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| SBE-Retreated PF-06700841 Responders in the Withdrawal Segment | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| SBE-Retreated PF-06651600 Responders in Retreatment Segment | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| SBE-Retreated Responders on PF-06700841 in Retreatment Segment | 0/15 (0%) | 1/15 (6.7%) | 8/15 (53.3%) |
| Cross Over Extension-PF-06651600 | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Cross Over Extension-PF-06700841 | 0/18 (0%) | 1/18 (5.6%) | 8/18 (44.4%) |
| Event | Treatment Period-Placebo | Treatment Period-PF-06651600 | Treatment Period-PF-06700841 | Single Blind Extension-Active Non-responders on PF-06651600 | Single Blind Extension-Placebo Non-responders on PF-06651600 | Single Blind Extension-Active Non-responders on PF-06700841 | Single Blind Extension-Placebo Non-responders on PF-06700841 | SBE-Non-Retreated PF-06651600 Responders in Withdrawal Segment | SBE-Retreated PF-06651600 Responders in Withdrawal Segment | SBE-Non-Retreated PF-06700841 Responders (Withdrawal Segment) | SBE-Retreated PF-06700841 Responders in the Withdrawal Segment | SBE-Retreated PF-06651600 Responders in Retreatment Segment | SBE-Retreated Responders on PF-06700841 in Retreatment Segment | Cross Over Extension-PF-06651600 | Cross Over Extension-PF-06700841 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 0/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 1/15 | 0/5 | 0/18 |
| Gastroenteritis salmonellaInfections and infestations | 0/47 | 0/48 | 1/47 | 0/16 | 0/17 | 0/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 0/15 | 0/5 | 1/18 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/47 | 0/48 | 2/47 | 0/16 | 0/17 | 0/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 0/15 | 0/5 | 0/18 |
| Event | Treatment Period-Placebo | Treatment Period-PF-06651600 | Treatment Period-PF-06700841 | Single Blind Extension-Active Non-responders on PF-06651600 | Single Blind Extension-Placebo Non-responders on PF-06651600 | Single Blind Extension-Active Non-responders on PF-06700841 | Single Blind Extension-Placebo Non-responders on PF-06700841 | SBE-Non-Retreated PF-06651600 Responders in Withdrawal Segment | SBE-Retreated PF-06651600 Responders in Withdrawal Segment | SBE-Non-Retreated PF-06700841 Responders (Withdrawal Segment) | SBE-Retreated PF-06700841 Responders in the Withdrawal Segment | SBE-Retreated PF-06651600 Responders in Retreatment Segment | SBE-Retreated Responders on PF-06700841 in Retreatment Segment | Cross Over Extension-PF-06651600 | Cross Over Extension-PF-06700841 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/47 | 4/48 | 11/47 | 2/16 | 0/17 | 1/5 | 1/12 | 1/8 | 0/14 | 1/9 | 2/14 | 2/14 | 1/15 | 1/5 | 3/18 |
| FatigueGeneral disorders | 3/47 | 0/48 | 0/47 | 0/16 | 1/17 | 0/5 | 1/12 | 0/8 | 0/14 | 2/9 | 0/14 | 0/14 | 0/15 | 0/5 | 0/18 |
| NasopharyngitisInfections and infestations | 6/47 | 6/48 | 4/47 | 0/16 | 2/17 | 0/5 | 2/12 | 0/8 | 1/14 | 1/9 | 0/14 | 3/14 | 1/15 | 1/5 | 0/18 |
| HaematuriaRenal and urinary disorders | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 1/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 0/15 | 0/5 | 0/18 |
| PruritusSkin and subcutaneous tissue disorders | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 1/5 | 1/12 | 0/8 | 0/14 | 0/9 | 1/14 | 0/14 | 0/15 | 1/5 | 0/18 |
| IgA nephropathyRenal and urinary disorders | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 1/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 0/15 | 0/5 | 0/18 |
| NephrolithiasisRenal and urinary disorders | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 1/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 0/15 | 0/5 | 0/18 |
| ProteinuriaRenal and urinary disorders | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 1/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 0/15 | 0/5 | 0/18 |
| Blood creatinine increasedInvestigations | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 1/5 | 1/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 1/15 | 0/5 | 0/18 |
| Herpes simplexInfections and infestations | 0/47 | 0/48 | 0/47 | 0/16 | 0/17 | 1/5 | 0/12 | 0/8 | 0/14 | 0/9 | 0/14 | 0/14 | 0/15 | 0/5 | 0/18 |
All participants received at least 1 dose of PF-06651600,PF-06700841 or matching placebo.
| Age, Continuous(years) | TP:Placebo | TP:PF-06651600 | TP:PF-06700841 | Total |
|---|---|---|---|---|
| Mean | 38.17 ± 14.22 | 36.88 ± 12.62 | 33.94 ± 11.43 | 36.33 ± 12.84 |
| Age, Customized(Participants) | TP:Placebo | TP:PF-06651600 | TP:PF-06700841 | Total |
|---|---|---|---|---|
| 18-44 Years | 31 | 33 | 40 | 104 |
| 45-64 Years | 15 | 14 | 6 | 35 |
| >=65 Years | 1 | 1 | 1 | 3 |
| Sex: Female, Male(Participants) | TP:Placebo | TP:PF-06651600 | TP:PF-06700841 | Total |
|---|---|---|---|---|
| Female | 29 | 37 | 32 | 98 |
| Male | 18 | 11 | 15 | 44 |
| Ethnicity (NIH/OMB)(Participants) | TP:Placebo | TP:PF-06651600 | TP:PF-06700841 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 | 10 |
| Not Hispanic or Latino | 45 | 45 | 42 | 132 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | TP:Placebo | TP:PF-06651600 | TP:PF-06700841 | Total |
|---|---|---|---|---|
| White | 45 | 38 | 36 | 119 |
| Black or African American | 0 | 4 | 3 | 7 |
| Asian | 2 | 3 | 3 | 8 |
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| other | 0 | 3 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2016 to primary completion in May 2019, 29 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 29 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PF-06651600 · PF-06700841